scholarly journals Recurrent Primary Cardiac Lymphoma on Aortic Valve Allograft: Implications for Therapy

2014 ◽  
Vol 41 (5) ◽  
pp. 543-546 ◽  
Author(s):  
Fahmi J. Farah ◽  
Christopher D. Chiles

Primary malignant cardiac lymphomas associated with grafts are extremely rare: to our knowledge, only 6 cases of prosthesis-associated B-cell lymphoma have been reported. Ours is the first report of recurrent diffuse large B-cell lymphoma associated with aortic valve allografts. We treated a 60-year-old man who presented in early 2007 with aortic valve endocarditis. He underwent aortic valve replacement with an allograft; the resected native valve showed active endocarditis without tumor. In January 2011, the patient underwent repeat aortic valve replacement because of symptomatic aortic regurgitation. The explanted valve specimen displayed diffuse large B-cell lymphoma. In September 2011, the patient presented with fever and a mass around the aortic valve. He died in January 2012. On autopsy, the explanted replacement valve displayed recurrent diffuse large B-cell lymphoma. The recurrent lymphoma on a new graft leads us to believe that this tumor is more aggressive than had been thought. We propose early systemic chemotherapy, in addition to tumor resection, for the possibility of a better prognosis. We discuss our patient's case and review the relevant medical literature.

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Christopher Larrimore ◽  
Annmarie Jaghab

This is a case of an elderly female who presented for follow-up ultrasound of the right breast after routine mammogram revealed a small benign mass. A subsequent ultrasound detected a small nodular mass that was described as benign in appearance. Although the patient was asymptomatic, a fine-needle biopsy was performed to rule out malignancy. Results from immunohistochemistry and FISH studies of the biopsy were positive for diffuse large B-cell lymphoma (DLBCL). The patient underwent surgery for lumpectomy and removal of breast implants. Intraoperative tissue samples were analyzed by pathology using both flow cytometry and microscopy, and results confirmed DLBCL. With total tumor resection and implant removal completed, the patient did not require additional treatments as the prognosis of DLBCL status post implant removal is excellent. She returned for follow-up six months later and has since had no signs of reoccurrence.


2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii69-iii69
Author(s):  
A E Hasturk ◽  
E E Eyupoglu ◽  
G Gel ◽  
C Gokce

Abstract Diffuse large B-cell lymphoma of the scalp with extra and intracranial extension without systemic invasion in a non-immune compromised patient is extremely rare. It should be considered in the differential diagnosis of scalp masses and meningeal lesions. Early diagnosis and surgical treatment is associated with a good outcome. 74 years old male patient with no known history of malignancy came to our clinic for left frontal swelling. He had no systemic cancer involvement. Contrast-enhanced cranial MRI showed a mass lesion invading left frontal skin, subcutaneous tissue, temporal muscle, bone and the underlying dural layer (Figure 1). Surgical excision was decided and after planning with the plastic surgery consultation, the patient was taken into surgery. Skin was lifted with a left frontal flap and the invasion was observed. Skin flap was placed down and the tumoral tissue was totally excised with a margin of normal bone tissue. The pathology assessment of the frozen specimen was found concordant with lymphoma. No injury or invasion of the dura was seen macroscopically. After dural closure, metacrilate cranioplasty was performed in order to replace the removed bone flap. Afterwards patient was handed over to the plastic surgeon. To ensure tumor resection with a safe margin, a transposition scalp flap was designed in the parieto-occipital region. The flap was raised in the supraperiosteal plane with preservation of the pericranium and it was transferred to the defect site. In addition, the flap donor area was reconstructed with a split-thickness skin graft taken from the right thigh region. Then, a wound dressing was applied to the surgical area and opened on postoperative 4th day. No complications such as necrosis, hematoma, infection or wound dehiscence occurred postoperatively. Both the graft and the flap completely healed (Figure 2). The patient showed no new neurological deficits or wound problems postoperatively and did not experience any problems both in plastic surgical and neurosurgical follow-up period (Figure 3). The final pathology result reported as diffuse large B cell lymphoma with invasion of the skin, subcutaneous tissue, temporal muscle and bone. Afterwards, medical treatment was planned with consultation to the hematology and radiotherapy clinics. Primary Non-Hodgkin’s lymphoma (NHL) extending extra cranially and intra cranially without any systemic or skeletal findings is extremely rare. These lesions usually get misdiagnosed as they mimic other conditions such as meningiomas. Both radiological and histopathological diagnoses are very important. Radical surgical resection and reconstruction must be contemplated in treatment and also chemotherapy and radiotherapy alternatives should be considered. Malignant NHL should be taken into account for differential diagnosis in the mass lesions of the scalp.


Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.


Sign in / Sign up

Export Citation Format

Share Document